Ziopharm Oncology (United States)

Institution (Company)

Homepage ROR

Also Known As

Ziopharm Oncology (United States)

186

Publications

10.9K

Citations

Authors

Concepts

About

Ziopharm Oncology (United States) is a company institution in Boston, United States known for medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	94	5.6K
2	Natural Sciences	7	16	662
3	Engineering	2	2	62
4	Health Sciences	1	1	24
5	Public Health	1	1	17

Ziopharm Oncology (United States)

186

Publications

10.9K

Citations

Page 1

	Year	Citations
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma Christine G. Lian, Yufei Xu, Craig J. Ceol, Cell ChromatinPhotocarcinogenesisMelanomaEpigenetic HallmarkMedicine	2012	795
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells Lenka V. Hurton, Harjeet Singh, Amer Najjar, Proceedings of the National Academy of Sciences	2016	439
Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon Sugunya Utaida, Paul M. Dunman, Daphne Macapagal, Microbiology	2003	325
Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells Boris Shor, Jiang Wu, Quazi Shakey, Journal of Biological Chemistry Tumor BiologyTranscriptional RegulationSignaling PathwayCell RegulationMedicine	2010	183
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells Adina Vultur, Ralf Buettner, Claudia Kowolik, Molecular Cancer Therapeutics	2008	165
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules Malathi Hari, Frank Loganzo, Tami Annable, Molecular Cancer Therapeutics CytoskeletonImmunotherapeuticsCancer BiologyCellular PhysiologyTumor Biology	2006	146
Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization Wenshan Hao, Chao-Pei Betty Chang, Cheng‐Chung Tsao, Journal of Biological Chemistry	2010	138
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Frank Loganzo, Carolyn Discafani, Tami Annable, PubMed Microtubule OrganizationPharmacotherapyTripeptide HemiasterlinTumor BiologyDrug Resistance	2003	137
SKI-606, a Src/Abl Inhibitor with<i>In vivo</i>Activity in Colon Tumor Xenograft Models Jennifer M. Golas, Judy Lucas, Carlo Etienne, Cancer Research Cancer BiologyTumor BiologySignaling PathwayGastrointestinal OncologyReceptor Tyrosine Kinase	2005	133
American Telemedicine Association clinical guidelines for telepathology Liron Pantanowitz, Kim Dickinson, Andrew Evans, Journal of Pathology Informatics	2014	107

Page 1